Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience

Haemophilia. 2016 Jul;22(4):e338-41. doi: 10.1111/hae.12973. Epub 2016 Jun 22.

Authors

B Rossi¹, P Blanche¹, V Roussel-Robert², A Berezné¹, S Combe², P Coppo³, L Guillevin¹, C Le Jeunne¹, L Mouthon¹, N Ounnoughene², N Stieltjes², M Groh¹

Affiliations

¹ Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France.
² Centre des hémophiles, Hôpital Cochin, Assistance Publique Hôpitaux de Paris Université Paris Descartes, Paris, France.
³ Department of Hematology, Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie, Paris, France.

PMID: 27329210
DOI: 10.1111/hae.12973

No abstract available

Publication types

Letter

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Adult
Aged
Aged, 80 and over
Antibodies, Neutralizing / blood
Cyclophosphamide / therapeutic use
Factor VIII / analysis
Female
Hemophilia A / drug therapy*
Hemorrhage / prevention & control
Humans
Immunosuppressive Agents / therapeutic use
Male
Middle Aged
Remission Induction
Retrospective Studies
Rituximab / therapeutic use*
Young Adult

Substances

Adrenal Cortex Hormones
Antibodies, Neutralizing
Immunosuppressive Agents
Rituximab
Cyclophosphamide
Factor VIII

Supplementary concepts

Factor 8 deficiency, acquired